NASDAQ:DRUG Bright Minds Biosciences (DRUG) Stock Price, News & Analysis $47.21 +25.51 (+117.56%) (As of 10/18/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Bright Minds Biosciences Stock (NASDAQ:DRUG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$34.00▼$79.0250-Day Range$1.01▼$47.2152-Week Range$0.93▼$79.02Volume27.24 million shsAverage Volume881,444 shsMarket Capitalization$209.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Read More… Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade Bright Minds Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks48th Percentile Overall ScoreDRUG MarketRank™: Bright Minds Biosciences scored higher than 48% of companies evaluated by MarketBeat, and ranked 629th out of 1,014 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Bright Minds Biosciences.Read more about Bright Minds Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bright Minds Biosciences is -69.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bright Minds Biosciences is -69.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBright Minds Biosciences has a P/B Ratio of 36.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Bright Minds Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.95% of the float of Bright Minds Biosciences has been sold short.Short Interest Ratio / Days to CoverBright Minds Biosciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bright Minds Biosciences has recently decreased by 19.64%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBright Minds Biosciences does not currently pay a dividend.Dividend GrowthBright Minds Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.95% of the float of Bright Minds Biosciences has been sold short.Short Interest Ratio / Days to CoverBright Minds Biosciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bright Minds Biosciences has recently decreased by 19.64%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment0.49 News SentimentBright Minds Biosciences has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Bright Minds Biosciences this week, compared to 0 articles on an average week.Search Interest47 people have searched for DRUG on MarketBeat in the last 30 days. MarketBeat Follows20 people have added Bright Minds Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Bright Minds Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,060,428.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders42.66% of the stock of Bright Minds Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.52% of the stock of Bright Minds Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bright Minds Biosciences' insider trading history. DRUG Stock News HeadlinesMarketBeat Week in Review – 10/14 - 10/18 (DRUG)Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election.October 19 at 7:00 AM | marketbeat.comBright Minds Biosciences Inc. (NASDAQ:DRUG) Major Shareholder Cormorant Asset Management, Lp Acquires 372,591 SharesOctober 18 at 7:29 AM | insidertrades.comTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…October 19, 2024 | Timothy Sykes (Ad)Bright Minds Biosciences Stock Surges Almost 1,500%Bright Minds Biosciences (NASDAQ: DRUG) soared 1,445% in a single day, trading over 100 million shares without any news.October 16 at 8:46 AM | marketbeat.comCormorant Asset Management, Lp Acquires 372,591 Shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG) StockOctober 19 at 5:05 AM | americanbankingnews.comBright Minds rebounds after $35M private placementOctober 18 at 3:17 PM | msn.comWhat's Going On With Bright Minds Biosciences Stock Friday?October 18 at 3:17 PM | msn.comBright Minds Biosciences Announces US$35 Million Non-Brokered Private PlacementOctober 18 at 6:50 AM | globenewswire.comSee More Headlines DRUG Stock Analysis - Frequently Asked Questions How have DRUG shares performed this year? Bright Minds Biosciences' stock was trading at $1.43 at the beginning of the year. Since then, DRUG stock has increased by 3,201.4% and is now trading at $47.21. View the best growth stocks for 2024 here. How were Bright Minds Biosciences' earnings last quarter? Bright Minds Biosciences Inc. (NASDAQ:DRUG) issued its earnings results on Wednesday, August, 14th. The company reported $0.04 earnings per share (EPS) for the quarter. When did Bright Minds Biosciences' stock split? Bright Minds Biosciences's stock reverse split before market open on Friday, July 14th 2023. The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Bright Minds Biosciences? Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Bright Minds Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bright Minds Biosciences investors own include HubSpot (HUBS), Blink Charging (BLNK), ConocoPhillips (COP), Domino's Pizza (DPZ), Netflix (NFLX), ForgeRock (FORG) and SoFi Technologies (SOFI). Company Calendar Last Earnings8/14/2024Today10/19/2024Next Earnings (Estimated)1/03/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DRUG CUSIPN/A CIK1827401 Webbrightmindsbio.com Phone64-7407-2515FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.55% Return on Assets-53.79% Debt Debt-to-Equity RatioN/A Current Ratio35.07 Quick Ratio35.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book36.32Miscellaneous Outstanding Shares4,434,000Free Float2,542,000Market Cap$209.33 million OptionableNot Optionable Beta1.56 This page (NASDAQ:DRUG) was last updated on 10/19/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredAI Detects Profit Surge On MondayThis has given investors the opportunity to beat the market by 1,700% and a 100% win rate to begin the year.Monument Traders Alliance | SponsoredDeFi Coin on Verge of Breakout!Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this ...Crypto 101 Media | SponsoredExpert issues rare "All In" buy alert on $6 gold stockGold is SOARING – here's what you need to do Everything is lining up perfectly for a historic gold bull run...Stansberry Research | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredWhat do Nvidia and Amazon have in common?What do Nvidia and Amazon have in common? Well, other than being worth trillions… Both chose to collaborate wi...Miso Robotics | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Bright Minds Biosciences Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.